FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new compounds of formula 1a: , wherein Q1 and Q2, each separately and independently is specified in a group consisting of N and C-Z6, provided both Q1 and Q2 are not C-Z6 simultaneously; E1 represents phenyl, and wherein the cycle E1 is substituted by one or more residues R16, and wherein the cycle E1 is substituted by one or more residues R18; wherein A is specified in a group consisting of phenyl or pyrazolyl; G1 means pyrazolyl; the cycle A is substituted in any substituted position by one residue A1, wherein A1 is specified in a group consisting of A2 and A3; A2 and A3 are those as specified in cl.1 of the patent claim, the cycle A is optionally substituted by one or more residues R2; X2 represents a direct bond wherein E1 is independently bound to the group NR3 in formula 1a; X3 represents -O-; V and V2 represent H2, and VI is independently specified in a group consisting of H2 or O; each Z2 is independently and separately specified in a group consisting of hydrogen, C1-C6-alkyl; each Z3 is independently and separately specified in a group consisting of H, C1-C6-alkyl, branched C3-C7-alkyl and - (CH2)nN(R4)2; each Z4 represents H; each Z6 is independently and separately specified in a group consisting of H, C1-C6-alkyl, branched C3-C7-alkyl, hydroxyl, hydroxy-C3-C6-alkyl, branched hydroxy-C2-C6-alkyl-, (R3)2N-, (R4)2N-, -N(R3)C(O)R8, C(O)N(R4)2, halogen, -(CH2)nG1 and -R17; each R2 is specified in a group consisting of C1-C6-alkyl and branched C3-C8-alkyl; each R3 represents H; each R4 represents H, C1-C6-alkyl or branched C3-C7-alkyl; each R8 is independently and separately specified in a group consisting of C1-C6-alkyl and branched C3-C7-alkyl; each R16 is independently and separately specified in a group consisting of C1-C6-alkyl, branched C3-C7-alkyl, halogen and a cyano group; each R17 represents pyrazolyl; wherein R17 may be additionally substituted by one or more residues Z2 or Z3; R18 represents hydrogen; and n is equal to 0-6; p is equal to 1-4; q is equal to 2-6; r is equal to 0 or 1; t is equal to 1-3, v is equal to 1 or 2. Besides, the invention describes a method for modulation of wild-type kinase activity, a pharmaceutical composition for treating hyperproliferative diseases in cancer in mammals; there are also described methods of treating cancer in a patient.
EFFECT: there are prepared and described new compounds which can find the application in modulation of kinase activity.
20 cl, 56 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
AZABICYCLOCOMPOUND AND ITS SALT | 2010 |
|
RU2565078C2 |
NOVEL COUMARIN DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | 2007 |
|
RU2428420C2 |
HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
KINASE INHIBITORS | 2013 |
|
RU2637944C2 |
PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILLAR TANGLES | 2015 |
|
RU2695373C2 |
NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | 2005 |
|
RU2330021C2 |
PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILLARY TANGLES | 2015 |
|
RU2788916C2 |
ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | 2011 |
|
RU2535671C1 |
NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION BASED THEREON, USE THEREOF AND METHOD OF TREATING AND/OR PREVENTING DISEASE | 2009 |
|
RU2474575C2 |
Authors
Dates
2013-05-20—Published
2007-10-11—Filed